Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.47 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.43 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22045815 | 0.92 | MAP2K1 (0.57) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP3A4 | |
| SCHEMBL24906169 | 0.91 | MAP2K1 (0.40) | MAP2K1MAP2K2KCNH2 | |
| SCHEMBL24906368 | 0.88 | MAP2K1 (0.50) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL26047280 | 0.88 | MAP2K1 (0.50) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL24906381 | 0.88 | MAP2K1 (0.50) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL24906179 | 0.88 | FLT1 (0.38) | MAP2K1MAP2K2CYP3A4CYP2C19 | |
| SCHEMBL24906168 | 0.87 | MAP2K1 (0.43) | MAP2K1MAP2K2 | |
| SCHEMBL24349753 | 0.85 | MAP2K1 (0.47) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL24906390 | 0.83 | MAP2K1 (0.48) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP3A4 | |
| SCHEMBL22045848 | 0.83 | MAP2K1 (0.50) | MAP2K1MAP2K2MAP2K5EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885MAP2K5 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.